Hagens Berman said it is investigating Embecta Corp. after a proposed securities class action was filed in the U.S. District Court for the District of New Jersey, while Glancy Prongay Wolke & Rotter LLP separately reminded investors of an Aug. 17, 2026 deadline to seek lead plaintiff status. The complaint alleges Embecta and its management misrepresented the stability of the company’s core insulin pen needle business and maintained guidance that was misleading or unattainable during the Nov. 25, 2025 to May 4, 2026 class period, despite competitive share losses and weakness in the U.S. pen needle market and retail channel. On May 5, 2026, Embecta reported second-quarter fiscal 2026 results showing revenue fell more than 14%, largely due to weak pen needle sales, lowered full-year guidance, cut adjusted EPS guidance by about 43% at the midpoint, and reduced its quarterly dividend 93% to $0.01 from $0.15 per share. Shares fell $5.35, or 57.8%, to close at $3.90 that day. Investors may seek appointment as lead plaintiff, but class members do not need to take action now to remain in the putative class.